Diabetic Cataract—Pathogenesis, Epidemiology and Treatment by Pollreisz, Andreas & Schmidt-Erfurth, Ursula
Hindawi Publishing Corporation
Journal of Ophthalmology
Volume 2010, Article ID 608751, 8 pages
doi:10.1155/2010/608751
Review Article
DiabeticCataract—Pathogenesis, Epidemiology
and Treatment
AndreasPollreiszandUrsulaSchmidt-Erfurth
Department of Ophthalmology and Optometry, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
Correspondence should be addressed to Ursula Schmidt-Erfurth, ursula.schmidt-erfurth@meduniwien.ac.at
Received 11 December 2009; Accepted 2 April 2010
Academic Editor: Mark Petrash
Copyright © 2010 A. Pollreisz and U. Schmidt-Erfurth. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Cataract in diabetic patients is a major cause of blindness in developed and developing countries. The pathogenesis of diabetic
cataract development is still not fully understood. Recent basic research studies have emphasized the role of the polyol pathway
in the initiation of the disease process. Population-based studies have greatly increased our knowledge concerning the association
between diabetes and cataract formation and have deﬁned risk factors for the development of cataract. Diabetic patients also have
a higher risk of complications after phacoemulsiﬁcation cataract surgery compared to nondiabetics. Aldose-reductase inhibitors
and antioxidants have been proven beneﬁcial in the prevention or treatment of this sightthreatening condition in in vitro and in
vivo experimental studies. This paper provides an overview of the pathogenesis of diabetic cataract, clinical studies investigating
the association between diabetes and cataract development, and current treatment of cataract in diabetics.
1.Introduction
Worldwide more than 285 million people are aﬀected by
diabetes mellitus. This number is expected to increase to
439 million by 2030 according to the International Diabetes
Federation.
A frequent complication of both type 1 and type 2
diabetes is diabetic retinopathy, which is considered the
ﬁfth most common cause of legal blindness in the United
States [1]. In 95% of type 1 diabetics and 60% of type 2
diabetics with disease duration longer than 20 years, signs of
diabetic retinopathy occur. More severe cases of proliferative
diabetic retinopathy are seen in patients suﬀering from type
1 diabetes. Tight control of hyperglycemia, blood lipids, and
blood pressure has been shown to be beneﬁcial to prevent its
development or progression [2–4].
Cataract is considered a major cause of visual impair-
ment in diabetic patients as the incidence and progression of
cataract is elevated in patients with diabetes mellitus [5, 6].
The association between diabetes and cataract formation has
been shown in clinical epidemiological and basic research
studies. Due to increasing numbers of type 1 and type
2 diabetics worldwide, the incidence of diabetic cataracts
steadily rises. Even though cataract surgery, the most com-
mon surgical ophthalmic procedure worldwide, is an eﬀec-
tive cure, the elucidation of pathomechanisms to delay or
prevent the development of cataract in diabetic patients
remains a challenge. Furthermore, patients with diabetes
mellitushavehighercomplicationratesfromcataractsurgery
[7]. Both diabetes and cataract pose an enormous health
and economic burden, particularly in developing countries,
where diabetes treatment is insuﬃcient and cataract surgery
often inaccessible [8].
2.Pathogenesis of DiabeticCataract
The enzyme aldose reductase (AR) catalyzes the reduction
of glucose to sorbitol through the polyol pathway, a process
linked to the development of diabetic cataract. Extensive
research has focused on the central role of the AR pathway
as the initiating factor in diabetic cataract formation.
It has been shown that the intracellular accumulation of
sorbitol leads to osmotic changes resulting in hydropic lens
ﬁbers that degenerate and form sugar cataracts [9, 10]. In
the lens, sorbitol is produced faster than it is converted to
fructose by the enzyme sorbitol dehydrogenase. In addition,2 Journal of Ophthalmology
the polar character of sorbitol prevents its intracellular
removal through diﬀusion. The increased accumulation of
sorbitol creates a hyperosmotic eﬀect that results in an
infusion of ﬂuid to countervail the osmotic gradient. Animal
studies have shown that the intracellular accumulation of
polyols leads to a collapse and liquefaction of lens ﬁbers,
which ultimately results in the formation of lens opacities [9,
11]. These ﬁndings have led to the “Osmotic Hypothesis” of
sugar cataract formation, emphasizing that the intracellular
increase of ﬂuid in response to AR-mediated accumulation
of polyols results in lens swelling associated with complex
biochemicalchangesultimatelyleadingtocataractformation
[9, 10, 12].
Furthermore, studies have shown that osmotic stress
in the lens caused by sorbitol accumulation [13] induces
apoptosis in lens epithelial cells (LEC) [14] leading to
the development of cataract [15]. Transgenic hyperglycemic
mice overexpressing AR and phospholipase D (PLD) genes
became susceptible to develop diabetic cataract in contrast
to diabetic mice overexpressing PLD alone, an enzyme with
key functions in the osmoregulation of the lens [16]. These
ﬁndings show that impairments in the osmoregulation may
render the lens susceptible to even small increases of AR-
mediated osmotic stress, potentially leading to progressive
cataract formation.
The role of osmotic stress is particularly important for
the rapid cataract formation in young patients with type
1 diabetes mellitus [17, 18] due to the extensive swelling
of cortical lens ﬁbers [18]. A study performed by Oishi et
al. investigated whether AR is linked to the development of
adult diabetic cataracts [19]. Levels of AR in red blood cells
of patients under 60 years of age with a short duration of
diabetes were positively correlated with the prevalence of
posterior subcapsular cataracts. A negative correlation has
beenshownindiabeticpatientsbetweentheamountofARin
erythrocytes and the density of lens epithelial cells, which are
knowntobedecreasedindiabeticscomparedtonondiabetics
suggesting a potential role of AR in this pathomechanism
[20].
The polyol pathway has been described as the primary
mediator of diabetes-induced oxidative stress in the lens
[21]. Osmotic stress caused by the accumulation of sorbitol
induces stress in the endoplasmic reticulum (ER), the
principal site of protein synthesis, ultimately leading to the
generation of free radicals. ER stress may also result from
ﬂuctuations of glucose levels initiating an unfolded protein
response (UPR) that generates reactive oxygen species (ROS)
and causes oxidative stress damage to lens ﬁbers [22]. There
are numerous recent publications that describe oxidative
stress damage to lens ﬁbers by free radical scavengers in dia-
betics. However, there is no evidence that these free radicals
initiatetheprocessofcataractformationbutratheraccelerate
and aggravate its development. Hydrogen peroxide (H2O2)
is elevated in the aqueous humor of diabetics and induces
the generation of hydroxyl radicals (OH–) after entering
the lens through processes described as Fenton reactions
[23]. The free radical nitric oxide (NO￿), another factor
elevated in the diabetic lens [24] and in the aqueous humor
[25], may lead to an increased peroxynitrite formation,
which in turn induces cell damage due to its oxidizing
properties.
Furthermore, increased glucose levels in the aqueous
humor may induce glycation of lens proteins, a process
resulting in the generation of superoxide radicals (O2
−)
and in the formation of advanced glycation endproducts
(AGE) [26]. By interaction of AGE with cell surface receptors
such as receptor for advanced glycation endproducts in the
epithelium of the lens further O2
− and H2O2 are generated
[27].
In addition to increased levels of free radicals, diabetic
lenses show an impaired antioxidant capacity, increasing
their susceptibility to oxidative stress. The loss of antiox-
idants is exacerbated by glycation and inactivation of
lens antioxidant enzymes like superoxide dismutases [28].
Copper-zink superoxide dismutase 1 (SOD1) is the most
dominant superoxide dismutase isoenzyme in the lens [29],
whichisimportantforthedegradationofsuperoxideradicals
(O2
−) into hydrogen peroxide (H2O2) and oxygen [30].
The importance of SOD1 in the protection against cataract
development in the presence of diabetes mellitus has been
shown in various in vitro and in vivo animal studies
[31–33].
In conclusion, a variety of publications support the
hypothesis that the initiating mechanism in diabetic cataract
formation is the generation of polyols from glucose by AR,
which results in increased osmotic stress in the lens ﬁbers
leading to their swelling and rupture.
3.ClinicalStudiesInvestigating
the Incidence of DiabeticCataract
Severalclinicalstudieshaveshownthatcataractdevelopment
occurs more frequently and at an earlier age in diabetic
compared to nondiabetic patients [34–36].
Data from the Framingham and other eye studies
indicate a three to fourfold increased prevalence of cataract
in patients with diabetes under the age of 65, and up to
a twofold excess prevalence in patients above 65 [34, 37].
The risk is increased in patients with longer duration of
diabetes and in those with poor metabolic control. A special
type of cataract—known as snowﬂake cataract—is seen
predominantly in young type 1 diabetic patients and tends
to progress rapidly. Cataracts may be reversible in young
diabetics with improvement in metabolic control. The most
frequently seen type of cataract in diabetics is the age-related
or senile variety, which tends to occur earlier and progresses
more rapidly than in nondiabetics.
The Wisconsin Epidemiologic Study of Diabetic
Retinopathy investigated the incidence of cataract extraction
in people with diabetes. Furthermore, additional factors
associated with higher risk of cataract surgery were
determined. The 10-year cumulative incidence of cataract
surgery was 8.3% in patients suﬀering from type 1 diabetes
and 24.9% in those from type 2 diabetes. Predictors
of cataract surgery included age, severity of diabetic
retinopathy and proteinuria in type 1 diabetics whereas age
and use of insulin were associated with increased risk in
type 2 diabetics [38].Journal of Ophthalmology 3
A follow-up examination of the Beaver Dam Eye Study
cohort, consisting of 3684 participants 43 years of age
and older, performed 5 years after the baseline evaluation
showedanassociationbetweendiabetesmellitusandcataract
formation [39]. In the study, the incidence and progression
of cortical and posterior subcapsular cataract was associated
with diabetes. In addition, increased levels of glycated
hemoglobin were shown to be associated with an increased
risk of nuclear and cortical cataracts.
In a further analysis of the Beaver Dam Eye study
the prevalence of cataract development was studied in a
population of 4926 adults [40]. Diabetic patients were more
likely to develop cortical lens opacities and showed a higher
rate of previous cataract surgery than nondiabetics. The
analysis of the data proved that longer duration of diabetes
was associated with an increased frequency of cortical
cataract as well as an increased frequency of cataract surgery.
The aim of the population-based cross-sectional Blue
Mountains Eye Study was to examine the relationship
between nuclear, cortical, and posterior subcapsular cataract
in 3654 participants between the years 1992 to 1994 [41].
The study supported the previous ﬁndings of the harmful
eﬀects of diabetes on the lens. Posterior subcapsular cataract
was shown to be statistically signiﬁcantly associated with
diabetes. However, in contrast to the Beaver Dam Eye Study,
nuclear cataract showed a weak, not statistically signiﬁcant,
association after adjusting for other known cataract risk
factors.
A population-based cohort study of 2335 people older
than 49 years of age conducted in the Blue Mountains region
of Australia investigated associations between diabetes and
the 5-year incidence of cataract. The results of this longitudi-
nalstudyconductedbythesamegroupofinvestigatorsasthe
Blue Mountains Eye Study demonstrated a twofold higher
5-year incidence of cortical cataract in participants with
impaired fasting glucose. Statistically signiﬁcant associations
were shown between incident posterior subcapsular cataract
and the number of newly diagnosed diabetic patients
[42].
The Visual Impairment Project evaluated risk factors
for the development of cataracts in Australians. The study
showed that diabetes mellitus was an independent risk factor
for posterior subcapsular cataract when present for more
than 5 years [43].
A goal of the Barbados Eye study was to evaluate the
relationship between diabetes and lens opacities among 4314
black participants [44]. The authors found that diabetes
history (18% prevalence) was related to all lens changes,
especially at younger ages.
4. CataractSurgery inDiabeticPatients
Phacomulsiﬁcation is nowadays the preferred technique
in most types of cataract. This technique was developed
by Kelman in 1967 and was not widely accepted until
1996 [45]. It results in less postoperative inﬂammation
and astigmatism, more rapid visual rehabilitation and, with
modern foldable lenses, a lower incidence of capsulotomy
than with the outdated extracapsularsurgery. There has been
a recent shift in emphasis towards earlier cataract extraction
in diabetics. Cataract surgery is advisable before lens opacity
precludes detailed fundus examination.
While the overall outcomes of cataract surgery are
excellent, patients with diabetes may have poorer vision
outcomes than those without diabetes. Surgery may cause a
rapid acceleration of retinopathy, induce rubeosis or lead to
macular changes, such as macular edema or cystoid macular
edema [46, 47]. The worst outcomes may occur in operated
eyes with active proliferative retinopathy and/or preexisting
macular edema [48, 49].
In diabetics with or without evidence of diabetic
retinopathy the blood-aqueous barrier is impaired leading
to an increased risk of postoperative inﬂammation and
developmentofasight-threateningmacularedema,aprocess
that is exacerbated by cataract surgery [50–52]. Factors
that inﬂuence the amount of postoperative inﬂammation
and the incidence of clinical and angiographic cystoid
macular edema are duration of surgery, wound size and
posterior capsular rupture or vitreous loss. Liu et al. showed
that phacoemulsiﬁcation surgery aﬀects the blood-aqueous
barrier more severely in diabetic patients with proliferative
diabetic retinopathy than in patients with nonproliferative
diabeticretinopathyornondiabeticpatients[53].Ananalysis
of Medicare beneﬁciaries (n = 139759) from the years
1997 through 2001 revealed that the rate of cystoid macular
edema diagnosis after cataract surgery was statistically
signiﬁcantly higher in diabetic patients than in nondiabetics
[54].
Several clinical studies investigated the role of pha-
coemulsiﬁcation cataract surgery on the progression of
diabetic retinopathy. One year after cataract surgery, the
progression rate of diabetic retinopathy ranges between 21%
and 32% [55–58]. Borrillo et al. reported a progression
rate of 25% after a follow-up period of 6 months [59].
A retrospective review of 150 eyes of 119 diabetic patients
undergoing phacoemulsiﬁcation surgery showed a similar
progression of diabetic retinopathy in 25% of cases within
the follow-up period of 6–10 months [56].
A prospective study evaluating the onset or worsening
of macula edema at 6 months following cataract surgery
in patients with mild or moderate nonproliferative diabetic
retinopathy reported an incidence of 29% (30 of 104 eyes)
of macula edema based on angiographic data [60]. Krepler
et al. investigated 42 patients undergoing cataract surgery
and reported a progression of diabetic retinopathy of 12%
in operated versus 10.8% in nonoperated eyes during the
follow-up of 12 months [61]. During the same follow-
up period of 12 months, Squirrell et al. showed that out
of 50 patients with type 2 diabetes undergoing unilateral
phacoemulsiﬁcation surgery 20% of the operated eye and
16% of the nonoperated had a progression of diabetic
retinopathy [62]. Liao and Ku found in a retrospective study
that out of 19 eyes with preoperative mild to moderate non-
proliferative diabetic retinopathy 11 eyes (57.9%) showed
progressionofdiabeticretinopathy1yearaftersurgery,while
12 eyes (63.2%) had progressed 3 years postoperatively.
The progression rates were statistically signiﬁcant when
compared to eyes without preoperative retinopathy [63]. A4 Journal of Ophthalmology
recently published prospective study evaluated eyes from
50 diabetic patients with and without retinopathy after
cataract surgery by optical coherence tomography [64].
The authors reported an incidence of 22% for macula
edema following cataract surgery (11 of 50 eyes) while
macula edema did not occur in eyes without retinopa-
thy. When only eyes with conﬁrmed diabetic retinopathy
were evaluated (n = 26), the incidence for postoperative
macula edema and cystoid abnormalities increased to 42%
(11 of 26 eyes). Minimal changes from baseline values
in center point thickness were observed in eyes with no
retinopathy. Eyes with moderate nonproliferative diabetic
retinopathy or proliferative diabetic retinopathy developed
an increase from baseline of 145μm and 131μma t1
month and 3 month, respectively. The diﬀerence in retinal
thickening between the 2 groups at 1 and 3 months was
statistically signiﬁcant and among patients with retinopa-
thy inversely correlated with visual acuity improvements.
5. AnticataractTreatment
5.1. Aldose-Reductase Inhibitors. Aldose reductase inhibitors
(ARI)compriseavarietyofstructurallydiﬀerentcompounds
like plant extracts, animal tissues or speciﬁc small molecules.
In diabetic rats, plant ﬂavonids, such as quercitrin or the
isoﬂavonegenistein,havedelayeddiabeticcataractformation
[65–68]. Examples of natural products with known AR
inhibitory activity are extracts from indigenous plants like
Ocimum sanctum, Withania somnifera, Curcuma longa,
and Azadirachta indica or the Indian herbal Diabecon
[69, 70]. Levels of polyol in the lenses of rats have been
reduced by injection of intrinsic ARI containing extracts
from human kidney and bovine lenses [71]. Nonsteroidal
anti-inﬂammatory drugs, such as sulindac [72, 73], aspirin
[74, 75]o rn a p r o x e n[ 76] have been reported to delay
cataract in diabetic rats through a weak AR inhibitory
activity.
Several experimental studies support the role of ARI
in preventing and not only delaying diabetic cataract for-
mation. In a rat model of diabetes, animals were treated
with the AR inhibitor Renirestat [77]. The study reported
a reduction of sorbitol accumulation in the lens as com-
pared to untreated diabetic rats. Furthermore, in Ranirestat
treated diabetic rats there were no signs of lens damage
like degeneration, swelling, or disruption of lens ﬁbers
throughout the treatment period in contrast to the untreated
group.
In a similar study, diabetic rats were treated with a dif-
ferent ARI, Fidarestat [78]. Fidarestat treatment completely
prevented cataractous changes in diabetic animals. In dogs
the topically applied ARI Kinostat has been shown to reverse
the development of sugar cataracts [79].
Other ARI with a beneﬁcial eﬀect on diabetic cataract
prevention encompass Alrestatin [80], Imrestat [81], Ponal-
restat [82], Epalrestat [83], Zenarestat [84], Minalrestat [85],
or Lidorestat [86].
These studies provide a rationale for a potential future
use of ARI in the prevention or treatment of diabetic
cataracts.
5.2. Antioxidant Treatments of Diabetic Cataracts. As oxida-
tive damage occurs indirectly as a result of polyol accu-
mulation during diabetic cataract formation, the use of
antioxidant agents may be beneﬁcial.
An um be ro fd i ﬀerentantioxidants have beenreported to
delay cataract formation in diabetic animals. These include
theantioxidantalphalipoicacid,whichhasbeenshowntobe
eﬀective in both delay and progression of cataract in diabetic
rats [87].
Yoshida et al. demonstrated that the combined treat-
ment of diabetic rats with vitamin E, a lipid-soluble and
antioxidant vitamin, and insulin synergistically prevented
the development and progression of cataracts in the animals
[88].
Pyruvate, an endogenous antioxidant, has recently
gained attention for its inhibitory eﬀect on diabetic cataract
formation by reducing sorbitol formation and lipid peroxi-
dation in the lens [89]. A study performed by Varma et al.
showed that the incidence of cataract in diabetic rats was
lower in the pyruvate-treated group than in the untreated
control group [90]. Additionally, the severity of opacities
in the pyruvate-treated rats was minor than in the control
animals.Thebeneﬁcialeﬀectofpyruvateinthepreventionof
cataract is mainly attributed to its eﬀective scavenging ability
for reactive oxygen species generated by increased levels of
sugars in diabetic animals [91].
However, clinical observations in humans suggest that
the eﬀect of antioxidant vitamins on cataract development
is small and may not prove to be clinically relevant [92].
5.3. Pharmacological Agents for the Treatment of Mac-
ular Edema Following Cataract Surgery. Proinﬂammatory
prostaglandins have been shown to be involved in the mech-
anisms leading to ﬂuid leakage from perifoveal capillaries
into the extracellular space of the macular region [93].
Due to the ability of topical nonsteroidal anti-inﬂammatory
drugs (NSAIDs) to block the cyclooxygenase enzymes
responsible for prostaglandin production, studies suggested
that NSAIDs may also reduce the incidence, duration and
severity of cystoid macular edema [94–97] by inhibiting
the release and breakdown of the blood-retina barrier
[98, 99].
Nepafenac, a topical NSAID indicated for the prevention
and treatment of anterior segment pain and inﬂammation
after cataract surgery, has been used recently in clinical trials
to testits eﬃcacyinreducingtheincidenceofmacularedema
after cataract surgery. The active ingredient is a prodrug that
rapidly penetrates the cornea to form the active metabolite,
amfenac, by intraocular hydrolases particularly in the retina,
ciliary body epithelium and choroid [100].
A retrospective study compared the incidence of macular
edema after uneventful phacoemulsiﬁcation between 240
patients treated for 4 weeks with topical prednisolone
and 210 patients treated with a combination of pred-
nisolone and nepafenac for the same time. The authors
concluded that patients treated with topical prednisolone
alone had a statistically signiﬁcantly higher incidence of
macular edema than those treated with additional nepafenac
[101].Journal of Ophthalmology 5
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